{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:44:37Z","timestamp":1789584277925,"version":"build-2803163510"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck","award":["MSIP 52261"],"award-info":[{"award-number":["MSIP 52261"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To evaluate the combination of pembrolizumab, cisplatin and gemcitabine in recurrent platinum-resistant ovarian cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients received six cycles of chemotherapy with gemcitabine and cisplatin on day 1 and day 8 of a 21-day treatment cycle. Pembrolizumab was administered on day 1 of cycles 3\u20136 and as maintenance monotherapy in cycles 7\u201334. Palliative radiation to a non-target symptomatic lesion was allowed. The primary objective was overall response rate by RECIST 1.1 criteria. Secondary objectives included safety, progression-free survival, time to progression, duration of response and overall survival.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>An interim analysis for futility was performed at 18 evaluable patients. Overall response rate was 60%, duration of response was 4.9 months and time to progression was 5.2 months. Progression-free survival at 6 and 12 months was 43% and 5%. Median progression-free survival was 6.2 months and median overall survival was 11.3 months. In all patients, CA125 levels reflected response and progression. There were no pseudoprogression events. After receiving palliative radiation during pembrolizumab maintenance, a patient with recurrent ovarian clear cell carcinoma had an exceptional and durable response that is ongoing for greater than 2 years. After consultation with the sponsor, based on the modest duration of response observed at the interim analysis for futility, the decision was made to close the trial to further accrual.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The addition of pembrolizumab to cisplatin and gemcitabine did not appear to provide benefit beyond chemotherapy alone in patients with recurrent platinum-resistant ovarian cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0252665","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T18:02:06Z","timestamp":1622743326000},"page":"e0252665","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-3971","authenticated-orcid":true,"given":"Christine S.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Kamrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-8890","authenticated-orcid":true,"given":"Andre","family":"Rogatko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9236-1281","authenticated-orcid":true,"given":"Ilana","family":"Cass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobbie J.","family":"Rimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"4","key":"pone.0252665.ref001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"DM Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4 Suppl 11","key":"pone.0252665.ref002","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"GJ Peters","year":"1995","journal-title":"Seminars in oncology"},{"issue":"1","key":"pone.0252665.ref003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","article-title":"Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma","volume":"88","author":"PG Rose","year":"2003","journal-title":"Gynecologic oncology"},{"issue":"1","key":"pone.0252665.ref004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"RA Nagourney","year":"2003","journal-title":"Gynecologic oncology"},{"issue":"2","key":"pone.0252665.ref005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","article-title":"Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group","volume":"103","author":"CA Brewer","year":"2006","journal-title":"Gynecologic oncology"},{"issue":"17","key":"pone.0252665.ref006","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"TJ Lynch","year":"2012","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"pone.0252665.ref007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"European journal of cancer"},{"issue":"3","key":"pone.0252665.ref008","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"L Seymour","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"11","key":"pone.0252665.ref009","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue","volume":"140","author":"M Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"pone.0252665.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"R Simon","year":"1989","journal-title":"Controlled clinical trials"},{"key":"pone.0252665.ref011","volume-title":"The statistical analysis of failure time data. Wiley series in probability and mathematical statistics","author":"JD Kalbfleisch","year":"1980"},{"issue":"34","key":"pone.0252665.ref012","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.","volume":"33","author":"J Hamanishi","year":"2015","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"pone.0252665.ref013","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028","volume":"152","author":"A Varga","year":"2019","journal-title":"Gynecologic oncology"},{"issue":"7","key":"pone.0252665.ref014","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"UA Matulonis","year":"2019","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO."},{"issue":"3","key":"pone.0252665.ref015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.","volume":"5","author":"ML Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"pone.0252665.ref016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.gore.2019.06.003","article-title":"Checkpoint inhibitors in ovarian cancer: A review of preclinical data","volume":"29","author":"DW Doo","year":"2019","journal-title":"Gynecol Oncol Rep"},{"issue":"Suppl 24","key":"pone.0252665.ref017","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1002\/cncr.32520","article-title":"Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising","volume":"125","author":"A Gonzalez-Martin","year":"2019","journal-title":"Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0252665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T18:02:28Z","timestamp":1622743348000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0252665"}},"subtitle":[],"editor":[{"given":"Sudeep","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0252665","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]}}}